EGFR and non-small cell lung carcinoma: The PAPILLON study (NCT04538664) demonstrated that amivantamab with chemotherapy significantly improved PFS in advanced NSCLC with EGFR exon 20 insertions (median PFS, 11.4 months vs. 6.7 months; HR, 0.40; p < 0.001).119